Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1613)	7/1/1998 11:23:00 PM
From: Rick Strange	Read Replies (1) \| Respond to of 2205

Marshall, I'm surprised that no one has had any comment about The Wall Street Journal article yesterday about the ALL-STAR ANALYSTS. Maykin Ho of Goldman Sach, who won top honors for the third time in the biotech sector, was quoted as picking ATIS as a stock she liked. The other stocks she named were Amgen, Qiagen, Millennium, Agouron, and Akermes. Her stock picks in 1997 returned 57% vs 5% for all of the analysts in the biotechnology field. I'd anticipate Goldman reinstating a Buy now that she has made this statement in the WSJ.